Clinical depression or elevated depressive symptoms are widely recognized to be prospectively related to increased mortality and morbidity in healthy adults and in patients with coronary heart disease (CHD).
1 as a result of this evidence, the aHa has recommended that clinicians assess depression in patients with CHD.
1 to date, no such recommendation has been made for anxiety, as no consensus exists regarding the relationship between anxiety and CHD. two reports published in the Journal of the American College of Cardiology (JACC) have now provided evidence that anxiety could be an independent risk factor for cardiac events in some groups. 2, 3 anxiety is a ubiquitous condition and is considered the most common psychiatric disorder, with a 1-year prevalence of 18% in american adults. 4 anxiety disorders take many forms, including panic attacks, generalized anxiety disorder, phobias, social anxiety disorder, obsessive-compulsive disorder, and post-traumatic stress disorder. Diagnosis is typically based upon subjective mood and physiological correlates including excessive worry and rumination, difficulty controlling anxious thoughts, hyper vigilance, excessive sweating, heart palpitations, and increased urinary urgency. 4 these manifesta tions can be assessed by psychiatric interview and by a variety of psycho metric questionnaires, although no universally accepted 'goldstandard' instrument exists. many patients with chronically high levels of anxiety do not meet diag nostic criteria for an anxiety disorder because their symptoms fluctuate over time or are not associated with the psychophysio logical symptoms required to meet diagnostic criteria. Further complicating the clinical picture is the extent to which chronic worry affects help-seeking behavior. Concerns about health can promote the adoption of healthy lifestyle behaviors or more frequent doctor visits, which could reduce risk of CHD, or could result in avoidance of the health-care system. Generalized anxiety disorder has been associ ated with a low rate of help seeking.
Considerable overlap exists in the clinical presentation of anxiety and depressive symptoms. therefore, some researchers have suggested that anxiety and depression might share a common dimension of 'negative affect' , 5 although aspects of anxiety may independently increase CHD risk. Despite these common features, however, the evidence that anxiety is predictive of adverse events in patients with CHD, or that anxiety predisposes healthy individuals to develop CHD, is considerably less consistent than the evidence supporting the relationship between depressive symptoms and CHD. in fact, a number of studies have found an inverse relationship between levels of anxiety and cardiac outcomes. For example, data from the norwegian Hunt study, 6 in which a large (n >60,000) population-based sample was analyzed, showed reduced rates 7 in addition, the beneficial effects of anxiety on survival were noted in patients diagnosed as having CHD, provided that they had no history of myocardial infarction (mi). in patients with reduced left ventricular function after mi, high anxiety scores were associated with increased mortality. thus, the prognostic value of anxiety is complex and, for reasons that are not entirely clear, may depend on the presence and severity of CHD.
the papers published in JACC add to this growing literature and provide further evidence that anxiety is prospectively related to the subsequent development of CHD. in part owing to inconsistencies in the literature, roest and colleagues performed a meta-analysis of 20 prospective studies involving 249,846 initially healthy men and women aged 38-72 years, followed over an average of 11.2 years.
2 anxiety was assessed by a variety of measures. results indicated that anxious individuals were at increased risk of CHD events (hazard ratio [Hr] 1.26, 95% Ci 1.15-1.38, P <0.0001) and cardiac death (Hr 1.48, 95% Ci 1.14-1.92, P = 0.003), but not of nonfatal mi (Hr 1.43, 95% Ci 0.85-2.40, P = 0.180).
in a second study by Janszky and colleagues, 3 49,321 swedish men aged 18-20 years who were screened for military service in 1969-1970 were followed for CHD for 37 years. Participants were all male and presumably all white. almost 20% of conscripts were examined by a psychiatrist; depression (psychotic or neurotic depression), was present in 1% of the sample, while anxiety (anxiety neurosis) was present in 0.3% of the sample. results indicated that men diagnosed with having anxiety, but not depression, were more than twice as likely to develop CHD as their nonanxious counterparts.
the study by Janszky et al. 3 had a number of laudable strengths, including a large sample with complete follow-up information for virtually all participants. statistical analyses were adjusted for key CHD risk factors including clinic blood pressure, reported smoking, and physical activity (inferred from membership in sports clubs). However, because the CHD event rate was only 4%, the study lacked adequate power to examine the potential interaction of anxiety and depression; furthermore, it did not include minorities or women. this latter limitation is important because women are more than twice as likely to be diagnosed as having depression or anxiety disorders as men.
4 a person's gender might also be an important moderator of risk. watkins and colleagues 8 reported results from a prospective cohort study in 947 patients with CHD, in which female patients with high levels of phobic anxiety had a 1.6-fold increased risk of cardiac mortality and a twofold increased risk of sudden cardiac death. By contrast, no such relationship was observed in men. the frequent co-occurrence of anxiety and depression indicates that the two conditions might interact to potentiate cardiac risk. For example, Phillips et al. 9 reported that individuals with generalized anxiety disorder and depression were at greater risk for subsequent cardiac death than individuals with either condition alone.
Janszky et al.
3 also had to rely on an outdated psychiatric diagnostic system; newer diagnostic formulations distinguish between various subtypes of anxiety disorders. indeed, whether subtypes of anxiety disorders are differentially associated with varying levels of risk of different clinical manifestations of CHD, or whether the entire spectrum of anxiety disorders places individuals at increased risk of CHD events is not clear. For example, in the nurses' Health study cohort of 72,359 women with no history of CHD, women with high phobic anxiety scores were at a 1.3-fold increased risk of fatal CHD and a 1.6-fold increased risk of sudden cardiac death compared with those women with low phobic anxiety. 10 in summary, the two reports published in JACC provide evidence for the prog nostic value of anxiety in the development of CHD in apparently healthy adults. However, uncertainty remains about the role of anxiety in cardiac health. inconsistencies in the literature result from nonuniform assessment tools and complex interactions with CHD disease severity, patient gender, and comorbid conditions such as depression. research in this field will progress if common instruments for assessing anxiety are used, so that results can be compared across studies. Because of the high prevalence of comorbid anxiety and depression, evaluating the separate and joint effects of these two conditions on clinical outcomes will be important. a need also exists to quantify participants' actual exposure to the symptoms of anxiety to determine the relative importance of duration, severity, and frequency of recurrence of symptoms, and any treatment that participants receive over the course of the follow-up period. Future studies will also need to include diverse populations, including both healthy individuals and patients with CHD, and consider potential mechanisms by which various anxiety disorders are associated with clinical CHD events.
www.nature.com/nrcardio nEws & viEws the idea that an elevated circulating level of the sulfur-containing amino acid homocysteine is involved in the development of vascular occlusive disease was first proposed in 1969. the 'homocysteine theory' was brought forward by Kilmer mcCully, who showed that similar vascular lesions were found in two patients with different inborn errors that were both associated with high levels of homocysteine.
1 mcCully hypothesized that such lesions could be prevented with medical or dietary inter ventions aimed at lowering homocysteine level.
1 since the early 1990s, this theory has been substantiated by experimental data suggesting that an increased level of homocysteine might cause vascular lesions.
1 in addition, case-control and prospective cohort studies have demonstrated that circulating levels of homocysteine are associated with the incidence and prognosis of coronary artery disease and stroke. 1 in a meta-analysis of cohort studies conducted in healthy populations, Humphrey et al. concluded that, for each 5 μmol/l increment in plasma total homocysteine level, the risk of coronary events increases by 18% independently of traditional risk factors for coronary artery disease.
2 However, the results of the study of the effectiveness of additional reductions in Cholesterol and Homocysteine (searCH), 3 
now published in the Journal of the American Medical
Association, demonstrate that administration of homocysteine-lowering B vitamins has no beneficial effects on cardio vascular health.
oral administration of folic acid (the synthetic form of folate), alone or in combination with vitamin B 12 , lowers homocysteine level.
1 in searCH, 3 12,064 patients with a history of myocardial infarction were randomly assigned to receive 2 mg of folic acid plus 1 mg of vitamin B 12 , or placebo, to assess whether lowering homocysteine levels would be associated with a reduction in the incidence of major adverse cardio vascular events (maCes; defined as coronary death, myocardial infarction, and stroke) or revascularization. the average duration of intervention was 6.7 years.
3 this study is the largest of the homocysteine-lowering trials conducted to date, 4 and was powered to detect a 10% reduced risk of the primary end point with the B-vitamin treatment at a 5% significance level. the lack of benefit from B vitamins observed in searCH 3 is disappointing, but is in line with the results of the other large homocysteinelowering secondary-prevention trials conducted among patients with established cardio vascular or renal disease. 4 the positive message from searCH 3 was that the vitamin treatment was not associated with an increased risk of cancer, which has previously been suggested. 5, 6 Folic acid has been the cornerstone treatment in homocysteine-lowering B-vitamin trials, and has been given in doses ranging from 0.8 mg per day to 40 mg per day. 4 these doses far exceed the recommended dietary allowances of 0.4 mg per day. although folate status is a major determinant of circulating homocysteine level, vitamins B 12 , B 2 , and B 6 , and one-carbon donors such as choline and betaine are also involved in regulating homocysteine level.
1,7 the complexity of these interactions has been summarized in the concept of a 'B-vitamin cross-talking network' , which implies that the effect of one component on homocysteine depends on the levels of the others. 7 in terms of healthy nutrition, the inter actions between B vitamins in humans remind us that these micro nutrients are not present at high doses of a single vitamer in natural food, but rather at balanced and physio logical levels of multiple B vitamins. 8 an elevated circulating level of homocysteine is also associated with a variety of factors that do not primarily reflect B-vitamin status, including several risk factors for cardio vascular disease, such as smoking, low physical activity, high blood pressure, high total-cholesterol levels and impaired renal function. 9 notably, among patients with ischemic heart disease partici pating in two norwegian homocysteine-lowering trials, baseline plasma homo cysteine level was not an indepen dent predictor of cardio vascular events. How ever, homocysteine level, measured after 1-2 months of intervention with folic acid and vitamin B 12 , was a signifi cant predictor of subsequent maCes. 10 this finding could indicate that the fraction of plasma homocysteine not responsive to treatment with B vitamins is linked to cardio vascular disease progression.
there are several possible explanations why treatment with homocysteine-lowering B vitamins did not prevent cardiovascular events in searCH, 3 or in other secondaryprevention trials with hard clinical end points. 4 First, an elevated level of homocysteine could be an epiphenomenon related to processes involved in the development of vascular lesions and might not itself have a causal role. second, short-term (up to 7 years) treatment with B vitamins might not reverse or stop the progression of vascular occlusion in individuals with established disease. this idea does not, however, preclude a protective effect of long-term intervention in healthy individuals. third, high doses of single vitamins, or a combination of just a few vitamins, might not affect putative PrEvEnTion B vitamins and CVD-failure to find a simple solution
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The hope that a simple, affordable, and safe homocysteine-lowering intervention with folic acid and vitamin B 12 would improve outcomes for patients with established cardiovascular or renal disease has been crushed by the null results from large B-vitamin treatment trials completed to date.
